MORE THAN 70 COMPANIES CURRENTLY CLAIM TO MANUFACTURE PEPTIDE-BASED THERAPEUTICS
The in-house development of peptide API requires necessary expertise and capabilities, including design, construction and maintenance of a facility which demands significant capital investments. Therefore, several small drug developers and, at times, certain pharma giants as well, have started outsourcing their manufacturing operations to contract service providers. Over the years, the popularity of biologics has […]
MORE THAN 70 COMPANIES CURRENTLY CLAIM TO MANUFACTURE PEPTIDE-BASED THERAPEUTICS Read More »